177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma (LuDO-N)
A Phase II Trial of 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma
The LuDO-N Trial is a multi-centre phase II clinical trial on 177Lu-DOTATATE treatment of recurrent or relapsed high-risk neuroblastoma in children. The LuDO-N Trial builds on the experience from the previous LuDO Trial and utilises an intensified dosing schedule to deliver 2 doses over a 2-week period, in order to achieve a maximal effect on the often rapidly progressing disease. This strategy requires a readiness for autologous stem cell transplantation in all patients, but is not anticipated to increase the risk of long-term sequelae, since the cumulative radiation dose remains unchanged. The primary aim of the study is to assess the response to 177Lu-DOTATATE treatment at 1 and 4 months after end of treatment. Secondary aims are to assess survival and treatment-related toxicity. Additional aim are to correlate tumour dosimetry with response, correlate SSTR-2 expression with 68Ga-DOTATATE uptake and to correlate the uptake with the treatment response.
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Estágio
Estágio
- Fase 2
Contactos e Locais
Contato de estudo
Contato de estudo
- Nome: Jakob Stenman, MD PhD
- Número de telefone: 46 (0)51770000
- E-mail: jakob.stenman@regionstockholm.se
Estude backup de contato
- Nome: Kleopatra Georgantzi, MD
- Número de telefone: 46 (0)51770000
- E-mail: kleopatra.georgantzi@regionstockholm.se
Locais de estudo
-
-
Copenhagen
-
Copenhagen, Copenhagen, Dinamarca, DK-2100
- Recrutamento
- Rigshospitalet
-
Contato:
- Jesper S Brok, MD PhD
- E-mail: jesper.sune.brok@regionh.dk
-
Investigador principal:
- Jesper S Brok, MD PhD
-
-
-
-
-
Barcelona, Espanha
- Recrutamento
- Pediatric Cancer Center Barcelona, Sant Joan de Déu Barcelona Children's Hospital
-
Contato:
- Maite Gorostegui Obanos, MD
- Número de telefone: +34 93 280 40 00
- E-mail: maite.gorostegui@sjd.es
-
Investigador principal:
- Maite Gorostegui Obanos, MD
-
-
-
-
Utrecht
-
Utrecht, Utrecht, Holanda, NL-3584
- Recrutamento
- Princess Maxima Center for Pediatric Oncology
-
Contato:
- Max M van Noesel, MD PhD
- E-mail: M.M.vanNoesel@prinsesmaximacentrum.nl
-
Investigador principal:
- Max M van Noesel, MD PhD
-
-
-
-
Vilnius County
-
Vilnius, Vilnius County, Lituânia, LT-08406
- Recrutamento
- Vilnius University Hospital
-
Contato:
- Jelena Rascon, MD PhD
- E-mail: jelena.rascon@gmail.com
-
Investigador principal:
- Jelena Rascon, MD PhD
-
-
-
-
Oslo
-
Oslo, Oslo, Noruega, NO-0372
- Recrutamento
- Oslo University Hospital, Rikshospitalet
-
Contato:
- Kirsten Brunsvig Jarvis, MD
- E-mail: kirjar@ous-hf.no
-
Investigador principal:
- Kirsten Brunsvig Jarvis, MD
-
-
-
-
-
Glasgow, Reino Unido, G51 4TF
- Recrutamento
- GREATER GLASGOW HEALTH BOARD, Royal Hospital for Children
-
Contato:
- Diana Mcintosh, Consultant Paediatric Oncologi
- E-mail: Diana.Mcintosh2@nhs.scot
-
Investigador principal:
- Diana Mcintosh, MD
-
London, Reino Unido, NW1 2PG
- Recrutamento
- University College London Hospitals NHS FOUNDATION TRUST
-
Contato:
- Jenny Gains, Consultant in Clinical Oncolog
- Número de telefone: +44-203 447 4437
- E-mail: jenny.gains@nhs.net
-
Investigador principal:
- Jenny Gains, MD
-
London, Reino Unido, SW3 6JJ
- Recrutamento
- The Royal Marsden NHS Foundation Trust of Fulham Road
-
Contato:
- Sucheta Vaidya, Paediatric Oncologist
- E-mail: Sucheta.Vaidya@rmh.nhs.uk
-
Investigador principal:
- Sucheta Vaidya, MD
-
-
-
-
Stockholm County
-
Stockholm, Stockholm County, Suécia, SE-171 76
- Recrutamento
- Karolinska University Hospital
-
Investigador principal:
- Kleopatra Georgantzi, MD
-
Contato:
- Kleopatra Georgantzi, MD
- E-mail: kleopatra.georgantzi@regionstockholm.se
-
Contato:
- Jakob Stenman, MD PhD
- E-mail: jakob.stenman@regionstockholm.se
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Pathology 1.1. Histologically confirmed diagnosis of neuroblastoma 1.2. Immunohistochemical staining for somatostatin receptors (SSTR) performed from primary tumor tissue when available
- Relapsed or primary refractory high-risk neuroblastoma: INSS stage 4 disease or INRGSS stage M disease
- Age >18 months at the time of enrolment into this study
- Life expectancy of greater than 3 months
- Performance Status 5.1. Karnofsky > 50% (for patients > 12 years of age) 5.2. Lansky > 50% (for patients ≤ 12 years of age)
- Prior treatment 6.1. Two-week washout from any prior treatment 6.2. Patients must have recovery of hematological toxicity following previous therapy 6.3. Adequate recovery from major surgery prior to receiving study treatment
- Diagnostic imaging 7.1. Uptake in the primary tumor or metastatic tumour deposits on 68Ga-DOTATATE PET/CT at least higher than the liver uptake and performed within two months prior to registration 7.2. 123I-mIBG scintigraphy to be performed within two months prior to registration 7.3. CT or MRI of the primary tumor and bulky metastatic sites within two months prior to registration
- Laboratory requirements to be performed within 7 days prior to commencing trial treatment 8.1. Hematology: 8.1.1. Hemoglobin, If Hb is <120 g/L then patient will receive a blood transfusion prior to commencing trial treatment 8.1.2. Absolute neutrophil count > 1.0 x 109/L 8.1.3. Absolute Platelets > 50 x 109/L 8.2. Biochemistry: 8.2.1. Bilirubin within 1.5 x ULN 8.2.2. ALT within 2.5 x ULN 8.2.3. AST within 2.5 x ULN 8.2.4. GGT within 5 x ULN 8.2.5. ALP within 5 x ULN 8.2.6. Glomerular filtration rate >50mL/min/1.73m2 assessed by a recognised method, such as inulin, 51Cr-EDTA, 99mTc-DTPA or iohexol clearance and performed within 2 months prior to registration 8.2.7. Urinary catecholamine metabolites measured within 2 months prior to registration
- Peripheral blood stem cells (PBSC) 9.1. A minimum of 2 x106 CD34+ cells/kg (optimally 6 x106 CD34+ cells/kg) must be available for each study subject prior to registration
- Written informed consent from patient and/or parent(s) or legal guardian(s) in accordance with national regulations, prior to registration or any trial-related screening procedures
Exclusion Criteria:
- Not fit enough to undergo proposed study treatment, as assessed by national PI, considering precautions defined in the latest version of the 177Lutetium-DOTATATE SmPC.
- Pregnant or lactating patient
- Concurrent treatment with any anti-tumor agents
- Prior treatment with other radiolabeled somatostatin analogues
- Hypersensitivity to any component of the investigational drug 177Lutetium-DOTATATE
- Treatment with long-acting somatostatin analogues within 30 days, or with short-acting somatostatin analogues within 24 hours prior the administration of 177Lutetium-DOTATATE
- Hydronephrosis in either kidney on baseline MRI or CT; patients can still be eligible for inclusion if urinary tract obstruction can be ruled out by renography
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Experimental: 177Lu-DOTATATE
A total of two doses of 177Lu-DOTATATE will be administered intravenously. The minimum time between treatments is 2 weeks. |
A total of two doses of 177Lu-DOTATATE will be administered intravenously. A weight-based activity of 400 MBq kg-1 will be used for the first dose. The activity of the second dose will be calculated based on whole body activity scans as well as SPECT/CT scans to determine the absorbed kidney dose. The aim is to administer 177Lu-DOTATATE corresponding to a whole-body dose of 1,2 Gy, with a cumulative whole-body dose of about 2,4 Gy over two courses, and not exceeding a cumulative renal dose of 23 Gy, to avoid renal toxicity. The aim is to deliver two doses of 177Lu-DOTATATE two weeks apart. The minimum time between treatments is 2 weeks. The maximum time between treatments is 4 weeks. |
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Response by the Revised International Neuroblastoma Response Criteria (INRC) at 1 month after the completion of therapy
Prazo: 1 months following end of treatment
|
Treatment response assessed in accordance with the Revised International Neuroblastoma Response Criteria (INRC) |
1 months following end of treatment
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Response based on 68Ga-DOTATOC PET/CT imaging at 1 and 4 months after completion of therapy in measurable target lesions
Prazo: 1 and 4 months following end of treatment
|
Response based on 68Ga-DOTATOC PET/CT imaging after completion of therapy in measurable target lesions |
1 and 4 months following end of treatment
|
|
Response based on 123I-mIBG SPECT/CT imaging (when available) at 1 and 4 months after completion of therapy in measurable target lesions
Prazo: 1 and 4 months following end of treatment
|
Response based on 123I-mIBG SPECT/CT imaging (when available) after completion of therapy in measurable target lesions |
1 and 4 months following end of treatment
|
|
Response by the Revised INRC criteria at 4 months after the completion of therapy
Prazo: 4 months following end of treatment
|
Response by the Revised INRC criteria |
4 months following end of treatment
|
|
Progression-free survival
Prazo: Time from registration to progression or death, up to 5 years following end of treatment
|
Time to progress or death, whichever occurs first |
Time from registration to progression or death, up to 5 years following end of treatment
|
|
Overall survival - up to 5 years after End of Treatment
Prazo: Time from registration to the the date of death, up to 5 years following end of treatment
|
Overall survival |
Time from registration to the the date of death, up to 5 years following end of treatment
|
|
Hematological and renal toxicity according to CTCAE 5.0
Prazo: From first treatment dose until the date of first documented progression, assessed up to 60 months
|
Hematological and renal toxicity according to CTCAE 5.0 |
From first treatment dose until the date of first documented progression, assessed up to 60 months
|
Outras medidas de resultado
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Dosimetry (absorbed dose in Gy) in measurable target lesions and risk organs
Prazo: At every administered dose of 177Lu-DOTATATE throughout the trial treatment phase (5 years)
|
Measured by SPECT/CT |
At every administered dose of 177Lu-DOTATATE throughout the trial treatment phase (5 years)
|
|
Semi-quantitative analysis of the expression of SSTR-2 on immunohistochemistry in the primary tumor histology
Prazo: Throughout the trial treatment phase (5 years)
|
Semi-quantitative analysis of the expression of SSTR-2 on immunohistochemistry in the primary tumor histology |
Throughout the trial treatment phase (5 years)
|
|
The uptake on 68Gallium-DOTATOC PET/CT by SUVmax (maximum standardized uptake value) in measurable target lesions
Prazo: At end of treatment, and 1 and 4 months after end of treatment.
|
Measured by SUVmax (maximum standardized uptake value) |
At end of treatment, and 1 and 4 months after end of treatment.
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Investigadores
Investigadores
- Cadeira de estudo: Jakob Stenman, MD PhD, Karolinska University Hospital
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Neoplasias
- Neoplasias por Tipo Histológico
- Neoplasias Glandulares e Epiteliais
- Neoplasias Neuroepiteliais
- Tumores Neuroectodérmicos
- Neoplasias, Células Germinativas e Embrionárias
- Neoplasias, Tecido Nervoso
- Tumores Neuroectodérmicos Primitivos Periféricos
- Tumores Neuroectodérmicos Primitivos
- Neuroblastoma
- Lutetium lu 177 dotatato
Outros números de identificação do estudo
Outros números de identificação do estudo
- LuDO-N
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .